Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CPMV NASDAQ:ENVB OTCMKTS:GPLB NASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPMVMosaic ImmunoEngineering$0.40$0.48$0.25▼$1.00$2.91M-1.2466 shsN/AENVBEnveric Biosciences$0.97-2.5%$1.19$0.85▼$8.33$3.15M0.58319,973 shs127,704 shsGPLBGreen Planet Bioengineering$0.04$0.04$0.02▼$0.70$800K3.073,055 shsN/AQLGNQualigen Therapeutics$2.10+0.5%$2.33$1.61▼$10.45$3.54M-0.1542,570 shs24,867 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPMVMosaic ImmunoEngineering0.00%-49.28%-13.53%-25.26%-59.79%ENVBEnveric Biosciences0.00%+6.58%-12.62%-19.84%-86.97%GPLBGreen Planet Bioengineering0.00%0.00%0.00%-63.64%-90.00%QLGNQualigen Therapeutics0.00%+24.26%+19.32%-43.40%-72.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPMVMosaic ImmunoEngineering$0.40$0.48$0.25▼$1.00$2.91M-1.2466 shsN/AENVBEnveric Biosciences$0.97-2.5%$1.19$0.85▼$8.33$3.15M0.58319,973 shs127,704 shsGPLBGreen Planet Bioengineering$0.04$0.04$0.02▼$0.70$800K3.073,055 shsN/AQLGNQualigen Therapeutics$2.10+0.5%$2.33$1.61▼$10.45$3.54M-0.1542,570 shs24,867 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPMVMosaic ImmunoEngineering0.00%-49.28%-13.53%-25.26%-59.79%ENVBEnveric Biosciences0.00%+6.58%-12.62%-19.84%-86.97%GPLBGreen Planet Bioengineering0.00%0.00%0.00%-63.64%-90.00%QLGNQualigen Therapeutics0.00%+24.26%+19.32%-43.40%-72.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPMVMosaic ImmunoEngineering 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00931.03% UpsideGPLBGreen Planet Bioengineering 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.94) per shareN/AENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/A($4.12) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPMVMosaic ImmunoEngineering-$920K-$0.10N/A∞N/AN/AN/A-822.45%11/17/2025 (Estimated)ENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)GPLBGreen Planet BioengineeringN/AN/A0.00∞N/AN/AN/AN/AN/AQLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/12/2025 (Estimated)Latest GPLB, QLGN, ENVB, and CPMV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CPMVMosaic ImmunoEngineeringN/A-$0.02N/A-$0.02N/AN/A8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/A8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPMVMosaic ImmunoEngineeringN/A0.010.01ENVBEnveric BiosciencesN/A2.422.42GPLBGreen Planet BioengineeringN/AN/AN/AQLGNQualigen TherapeuticsN/A0.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPMVMosaic ImmunoEngineeringN/AENVBEnveric Biosciences13.82%GPLBGreen Planet BioengineeringN/AQLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipCPMVMosaic ImmunoEngineering80.99%ENVBEnveric Biosciences1.10%GPLBGreen Planet BioengineeringN/AQLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionableENVBEnveric Biosciences203.25 million3.21 millionNot OptionableGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionableQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableGPLB, QLGN, ENVB, and CPMV HeadlinesRecent News About These CompaniesFinancial Analysis: TherapeuticsMD (NASDAQ:TXMD) versus Qualigen Therapeutics (NASDAQ:QLGN)September 4, 2025 | americanbankingnews.comQualigen Therapeutics Amends Promissory Note with MarizymeAugust 27, 2025 | tipranks.comQualigen Therapeutics, Inc.: Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 30, 2025 | finanznachrichten.deQualigen Therapeutics Announces $4.5M Private PlacementJuly 29, 2025 | msn.comQualigen Therapeutics provides update on Nasdaq listing statusJuly 28, 2025 | msn.comQualigen Therapeutics Secures Nasdaq Compliance ExtensionJuly 28, 2025 | msn.comQualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 28, 2025 | finance.yahoo.comQualigen Therapeutics, Inc. Secures $4.5 Million Through Series A-3 Preferred Stock Private PlacementJuly 28, 2025 | quiverquant.comQQualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred StockJuly 28, 2025 | globenewswire.comQualigen Granted New Patents Covering 25 CountriesJuly 16, 2025 | manilatimes.netMQualigen Therapeutics shares surge after patent approvals in 25 countriesJuly 16, 2025 | msn.comQualigen Therapeutics, Inc. (QLGN) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQualigen Therapeutics faces potential Nasdaq delistingMay 21, 2025 | uk.investing.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics Faces Nasdaq Delisting NotificationMay 19, 2025 | tipranks.comQualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing DeficiencyMay 19, 2025 | quiverquant.comQQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-QMay 19, 2025 | globenewswire.comMarizyme, Inc. (MRZM) Latest Press Releases & Corporate News - Yahoo FinanceMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPLB, QLGN, ENVB, and CPMV Company DescriptionsMosaic ImmunoEngineering OTCMKTS:CPMV$0.40 0.00 (0.00%) As of 09/12/2025Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Enveric Biosciences NASDAQ:ENVB$0.97 -0.03 (-2.51%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.99 +0.02 (+2.07%) As of 09/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Green Planet Bioengineering OTCMKTS:GPLB$0.04 0.00 (0.00%) As of 09/12/2025Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.Qualigen Therapeutics NASDAQ:QLGN$2.10 +0.01 (+0.48%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$2.10 +0.00 (+0.24%) As of 09/12/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
